Natural Adventure LLC sold unapproved Purity sanitizer and essential oil products with COVID-19 treatment claims, FDA says.
What happened
FDA and FTC reviewed Natural Adventure's website and social media pages on February 26 and March 12, 2021. They found Purity Sanitizer with 70% Alcohol and Purity Essential Oil Blend offered for sale with claims that Ravintsara essential oil and the products could prevent or treat COVID-19. FDA says the products are unapproved new drugs and misbranded, and the sanitizer formulation does not fit the applicable hand sanitizer rule or FDA's temporary COVID-19 guidance.
What FDA found
The products are unapproved new drugs because they are sold with claims to prevent, treat, diagnose, or cure COVID-19 without FDA approval.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The products are misbranded drugs, meaning their labeling or claims are false or misleading.
section 502 of the FD&C Act, 21 U.S.C. § 352The company introduced or delivered these products across state lines, which is prohibited for such drugs.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The hand sanitizer label claims 'anti-bacterial' essential oils that are not allowed as active ingredients under the applicable over-the-counter antiseptic rule.
section 505G(a) of the FD&C Act; 1994 TFM as amendedThe hand sanitizer formulation is not consistent with FDA's temporary COVID-19 hand sanitizer guidance.
Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)The FTC says the company lacks adequate scientific evidence for coronavirus prevention or treatment claims for Purity Essential Oil Blend.
FTC Act, 15 U.S.C. 41 et seq.; COVID-19 Consumer Protection Act
What FDA wants
FDA and FTC ask the company to immediately stop selling the unapproved COVID-19 products and to email specific corrective steps within 48 hours, including documentation and a plan to prevent recurrence. If the company cannot complete the actions within 48 hours, it must explain the delay and give a timeline.
Who should pay attention
- e-commerce sellers of essential oils and hand sanitizers
- brands making health claims on websites or social media
- quality teams reviewing COVID-19-related product claims
This is a summary. Read the original letter on fda.gov.